Defendant
1 case as defendant.
I'll research MSN Laboratories to verify its profile.
Let me verify the litigation context.
MSN Laboratories Private Limited (commonly "MSN Labs," the pharma arm of MSN Group) is a privately held, independent Indian pharmaceutical company headquartered at MSN House, Sanath Nagar Industrial Estate, Hyderabad, Telangana. It was founded in 2003 by Dr. M. S. N. Reddy (operations began February 2004) and is not publicly listed. Size figures vary by source: the company's own materials cite roughly 14,000–20,000 employees globally, while third-party trackers (Crustdata, Revelio, credit reports) put headcount nearer 8,000–12,000; treat exact numbers as unverified. Reported turnover similarly ranges from the company's cited ~US$670M (FY2021-22) to over US$1B (FY2024-25) and press reports of a ~₹10,000 crore group business.
Operations. MSN is a fully integrated generics and API manufacturer. It reports 400–500+ active pharmaceutical ingredients and 300–400+ finished dosage formulations across ~35 therapeutic areas (oncology, cardiology, CNS, diabetes, nephrology, urology, gastroenterology, orthopaedics), with API and formulation manufacturing and R&D sites in India and the U.S., plus contract development and manufacturing (CDMS) and emerging biosimilar/peptide/oligonucleotide work. It claims the world's largest number of active U.S. Drug Master Files and 150–230+ ANDA filings. Its U.S. arm, MSN Pharmaceuticals, Inc. (20 Duke Road, Piscataway, New Jersey), is a wholly owned subsidiary and U.S. agent; MSN Life Sciences Private Limited is an Indian affiliate.
Litigation posture. MSN is unambiguously an operating company, not an NPE: in the tracked data it appears only as a defendant (0 plaintiff cases, 1 defendant case). Its patent litigation consists almost entirely of Hatch-Waxman ANDA/Paragraph IV suits brought by branded manufacturers, clustered in the District of Delaware and the District of New Jersey — both favored by brand plaintiffs — rather than plaintiff-friendly venues such as the Eastern District of Texas. MSN typically answers and files invalidity/non-infringement counterclaims.
Notable case. The tracked matter, Merck Sharp & Dohme Corp. v. MSN Laboratories et al. (D. Del.), follows that pattern. Related public dockets show MSN defending numerous ANDA suits in D.N.J. and D. Del. involving products such as sugammadex, ubrogepant, plecanatide, amifampridine, cabozantinib, and sacubitril/valsartan, sometimes alongside affiliates MSN Life Sciences and MSN Pharmaceuticals.
Settled by consent judgment; unless authorized by the settlement agreement, MSN is enjoined from infringing the '708 patent, and all claims, counterclaims, affirmative defenses, and demands were dismissed with prejudice.